Remyelination in demyelinating disease.
In multiple sclerosis, partial remyelination is conspicuous in many lesions, and is thought to contribute significantly to lasting recovery from acute relapse. However, myelin repair ultimately fails during progression of the disease, as disability and handicap accumulate. In this chapter we explore the biological background to myelin repair in CNS demyelinating disease, and the reasons underlying the failure of more widespread and lasting remyelination in multiple sclerosis. Experimental studies provide clear evidence that therapies promoting myelin repair can be highly successful in the CNS, and we discuss the clinical approaches which might allow the translation of these laboratory studies to neurological practice, together with some of the potential hazards and pitfalls likely to arise.
Scolding
N J
NJ
MRC Cambridge Centre for Brain Repair, University of Cambridge, UK.
Franklin
R J
RJ
D000818:Animals; D016380:Brain Tissue Transplantation; D017690:Cell Transplantation; D003711:Demyelinating Diseases / Q000503:physiopathology; D004195:Disease Models, Animal; D018450:Disease Progression; D006801:Humans; D007136:Immunoglobulins / Q000494:pharmacology; D009103:Multiple Sclerosis / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D009186:Myelin Sheath / Q000378:metabolism*; D009414:Nerve Growth Factors / Q000627:therapeutic use; D009416:Nerve Regeneration / Q000502:physiology*; D009836:Oligodendroglia / Q000502:physiology; D012075:Remission, Spontaneous; D013997:Time Factors
D007136:Immunoglobulins; D009414:Nerve Growth Factors